Grifols
Grifols, officially known as Grifols, S.A., is a global leader in the biopharmaceutical industry, headquartered in Barcelona, Spain (ES). Founded in 1940, the company has established a strong presence in key operational regions, including Europe, North America, and Latin America. Grifols specialises in the development of plasma-derived medicines, diagnostic solutions, and hospital products, with a commitment to improving patient health. The company is renowned for its innovative therapies, particularly in the treatment of rare and chronic diseases, setting it apart in a competitive market. Grifols has achieved significant milestones, including the expansion of its plasma collection network and advancements in immunology. With a robust market position, Grifols continues to be recognised for its contributions to healthcare, making it a trusted name in the biopharmaceutical sector.
DitchCarbon Score
How does Grifols's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Grifols's score of 47 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Grifols's reported carbon emissions
In 2023, Grifols reported total greenhouse gas emissions of approximately 1,191,922,000 kg CO2e. This includes 106,459,000 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and 98,106,000 kg CO2e from Scope 2 emissions, related to indirect emissions from the generation of purchased electricity, steam, heating, and cooling. Additionally, the company recorded 947,463,000 kg CO2e in Scope 3 emissions, which cover all other indirect emissions in the value chain. Grifols has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by 2030, using 2022 as the baseline year. Furthermore, the company targets a 25% reduction in absolute Scope 3 emissions, which include emissions from purchased goods and services, capital goods, fuel- and energy-related activities, and upstream transportation and distribution, also by 2030. These targets align with the Science Based Targets initiative (SBTi) and are designed to contribute to limiting global warming to 1.5°C. Overall, Grifols is actively working towards significant emissions reductions, demonstrating a commitment to sustainability and climate responsibility within the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 98,043,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 |
| Scope 2 | 120,493,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | 77,388,000 | 00,000,000 | 00,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Grifols is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
